<DOC>
	<DOCNO>NCT02375425</DOCNO>
	<brief_summary>The development surrogates predict HIV prevention product safety efficacy high priority . An ex vivo challenge model one promising surrogate . Colonic tissue expose rectally apply microbicides vivo challenge HIV lab show significant reduction HIV replication compare tissue expose placebo gel . Currently , ex vivo challenge model ectocervical vaginal tissue development Dezzutti lab Magee Womens Research Institute Pittsburgh , PA . Currently Reproductive Infectious Disease Research Group conduct study design answer important question ex vivo challenge model : HIV virus best use laboratory best indicator HIV infection . The propose study delineate investigate effect BV , HSV contraceptive use model . There two arm study ; first investigate impact HSV BV status second , contraceptive use . Vaginal cervical biopsy collect participant ex vivo challenge model .</brief_summary>
	<brief_title>Optimization ex Vivo Challenge : Reproductive Infections Contraception</brief_title>
	<detailed_description />
	<criteria>1 . Age 1845 2 . HIV uninfected . Note : woman participate recent research study HIV test result available study , suffice provide date test within 6 month enrollment visit trial . Otherwise , potential participant undergo test first study visit . 3 . Willing able give inform consent take place study 4 . Willing undergo pelvic examination genital biopsy HIV HSV test 5 . Willing provide contact information 6 . Agree sexually abstinent two week begin one week prior enrollment visit 1 . Menopausal 2 . Pregnant within 90 day last pregnancy 3 . Hysterectomy 4 . Use diaphragm , NuvaRing spermicide contraception 5 . Reports course antibiotic therapy 14 day prior enrollment 6 . Known history platelet disorder bleed disorder 7 . Participation another microbicide contraceptive study study involve cervical and/or vaginal biopsy within one month enrollment 8 . Pelvic exam finding concern cervicitis include abnormal cervical discharge , erythema edema 9 . Use spermicide spermicidelubricated condom within one week enrollment . 10 . Use internal vaginal device product exception tampon within one week enrollment 11 . Any condition opinion site investigator would preclude provision inform consent , make participation study unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>BV , HSV</keyword>
	<keyword>contraceptive</keyword>
	<keyword>ex vivo challenge model</keyword>
</DOC>